DESTINY-Breast04: Trastuzumab Deruxtecan in HR+/HER2-Low Metastatic Breast Cancer
Breast cancer specialists review key efficacy and safety data from the DESTINY-Breast04 trial investigating trastuzumab deruxtecan in patients with HR+/HER2-low metastatic breast cancer.
Video content above is prompted by the following questions:
- Please review key efficacy and safety data from the DESTINY-Breast04 trial, evaluating trastuzumab deruxtecan (T-DXd) in patients with HR+, HER2-low metastatic breast cancer.
- What are the clinical implications of these data in your practice?
- What notable adverse events (AEs) have you observed in your practice?
- What mitigation strategies have been implanted in your practice to combat AEs of special interest?
Recent Videos
Related Content
Vidal Discusses Differences in Duration and AEs With Adjuvant CDK4/6i in Breast Cancer
May 13th 2025Article
During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their different dosing approaches and safety profiles can affect their usage in breast cancer.
Read More
